APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immunodeficiency Virus (HIV)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Immunodeficiency Virus (HIV) Market Outlook and Growth Opportunities 2026

31 December 2025191 pages

Choose your research edition.

Industry ResearchHuman Immunodeficiency Virus (HIV) Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunodeficiency Virus (HIV) Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Human Immunodeficiency Virus (HIV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunodeficiency Virus (HIV) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunodeficiency Virus (HIV) Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Human Immunodeficiency Virus (HIV) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Immunodeficiency Virus (HIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Immunodeficiency Virus (HIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Immunodeficiency Virus (HIV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Immunodeficiency Virus (HIV) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Immunodeficiency Virus (HIV) market include Merck & Co., Inc., Mylan, AbbVie, ViiV Healthcare, Genentech, Inc., Genentech, Inc., Cipla, Inc., Bristol-Myers Squibb Company and Boehringer Ingelheim GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Human Immunodeficiency Virus (HIV) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Immunodeficiency Virus (HIV) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Immunodeficiency Virus (HIV) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human Immunodeficiency Virus (HIV) market.

Human Immunodeficiency Virus (HIV) Segment by Company

Merck & Co., Inc.

Mylan

AbbVie

ViiV Healthcare

Genentech, Inc.

Genentech, Inc.

Cipla, Inc.

Bristol-Myers Squibb Company

Boehringer Ingelheim GmbH

Boehringer Ingelheim GmbH

Human Immunodeficiency Virus (HIV) Segment by Type

Protease Inhibitors

NNRTIs

Coreceptor Antagonists

NRTIs

Entry and Fusion Inhibitors

Integrase Inhibitors

Human Immunodeficiency Virus (HIV) Segment by Application

Clinics

Hospitals

Labs

Human Immunodeficiency Virus (HIV) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human Immunodeficiency Virus (HIV) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human Immunodeficiency Virus (HIV) key companies, revenue, market share, and recent developments.

3. To split the Human Immunodeficiency Virus (HIV) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human Immunodeficiency Virus (HIV) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Immunodeficiency Virus (HIV) significant trends, drivers, influence factors in global and regions.

6. To analyze Human Immunodeficiency Virus (HIV) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunodeficiency Virus (HIV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunodeficiency Virus (HIV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunodeficiency Virus (HIV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Immunodeficiency Virus (HIV) industry.

Chapter 3: Detailed analysis of Human Immunodeficiency Virus (HIV) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human Immunodeficiency Virus (HIV) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human Immunodeficiency Virus (HIV) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Immunodeficiency Virus (HIV) Industry Trends Table 2. Human Immunodeficiency Virus (HIV) Industry Drivers Table 3. Human Immunodeficiency Virus (HIV) Industry Opportunities and Challenges Table 4. Human Immunodeficiency Virus (HIV) Industry Restraints Table 5. Global Human Immunodeficiency Virus (HIV) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Immunodeficiency Virus (HIV) Revenue Share by Company (2021-2026) Table 7. Global Human Immunodeficiency Virus (HIV) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human Immunodeficiency Virus (HIV) Key Company Manufacturing Base & Headquarters Table 9. Global Human Immunodeficiency Virus (HIV) Company, Product Type & Application Table 10. Global Human Immunodeficiency Virus (HIV) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human Immunodeficiency Virus (HIV) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Protease Inhibitors Table 15. Significant Companies of NNRTIs Table 16. Significant Companies of Coreceptor Antagonists Table 17. Significant Companies of NRTIs Table 18. Significant Companies of Entry and Fusion Inhibitors Table 19. Significant Companies of Integrase Inhibitors Table 20. Global Human Immunodeficiency Virus (HIV) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Human Immunodeficiency Virus (HIV) Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Human Immunodeficiency Virus (HIV) Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Human Immunodeficiency Virus (HIV) Sales Value Share by Type (2021-2026) Table 24. Global Human Immunodeficiency Virus (HIV) Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Clinics Table 26. Significant Companies of Hospitals Table 27. Significant Companies of Labs Table 28. Global Human Immunodeficiency Virus (HIV) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Human Immunodeficiency Virus (HIV) Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Human Immunodeficiency Virus (HIV) Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Human Immunodeficiency Virus (HIV) Sales Value Share by Application (2021-2026) Table 32. Global Human Immunodeficiency Virus (HIV) Sales Value Share by Application (2027-2032) Table 33. Global Human Immunodeficiency Virus (HIV) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Human Immunodeficiency Virus (HIV) Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Human Immunodeficiency Virus (HIV) Sales Value Share by Region (2021-2026) Table 36. Global Human Immunodeficiency Virus (HIV) Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Human Immunodeficiency Virus (HIV) Sales Value Share by Region (2027-2032) Table 38. Global Human Immunodeficiency Virus (HIV) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Human Immunodeficiency Virus (HIV) Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Human Immunodeficiency Virus (HIV) Sales Value Market Share by Country (2021-2026) Table 41. Global Human Immunodeficiency Virus (HIV) Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Human Immunodeficiency Virus (HIV) Sales Value Market Share by Country (2027-2032) Table 43. Merck & Co., Inc. Company Information Table 44. Merck & Co., Inc. Business Overview Table 45. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Product Portfolio Table 47. Merck & Co., Inc. Recent Development Table 48. Mylan Company Information Table 49. Mylan Business Overview Table 50. Mylan Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Mylan Human Immunodeficiency Virus (HIV) Product Portfolio Table 52. Mylan Recent Development Table 53. AbbVie Company Information Table 54. AbbVie Business Overview Table 55. AbbVie Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. AbbVie Human Immunodeficiency Virus (HIV) Product Portfolio Table 57. AbbVie Recent Development Table 58. ViiV Healthcare Company Information Table 59. ViiV Healthcare Business Overview Table 60. ViiV Healthcare Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. ViiV Healthcare Human Immunodeficiency Virus (HIV) Product Portfolio Table 62. ViiV Healthcare Recent Development Table 63. Genentech, Inc. Company Information Table 64. Genentech, Inc. Business Overview Table 65. Genentech, Inc. Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Genentech, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio Table 67. Genentech, Inc. Recent Development Table 68. Genentech, Inc. Company Information Table 69. Genentech, Inc. Business Overview Table 70. Genentech, Inc. Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Genentech, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio Table 72. Genentech, Inc. Recent Development Table 73. Cipla, Inc. Company Information Table 74. Cipla, Inc. Business Overview Table 75. Cipla, Inc. Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Cipla, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio Table 77. Cipla, Inc. Recent Development Table 78. Bristol-Myers Squibb Company Company Information Table 79. Bristol-Myers Squibb Company Business Overview Table 80. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Product Portfolio Table 82. Bristol-Myers Squibb Company Recent Development Table 83. Boehringer Ingelheim GmbH Company Information Table 84. Boehringer Ingelheim GmbH Business Overview Table 85. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Product Portfolio Table 87. Boehringer Ingelheim GmbH Recent Development Table 88. Boehringer Ingelheim GmbH Company Information Table 89. Boehringer Ingelheim GmbH Business Overview Table 90. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Product Portfolio Table 92. Boehringer Ingelheim GmbH Recent Development Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Human Immunodeficiency Virus (HIV) Product Image Figure 2. Global Human Immunodeficiency Virus (HIV) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immunodeficiency Virus (HIV) Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Immunodeficiency Virus (HIV) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Protease Inhibitors Image Figure 8. NNRTIs Image Figure 9. Coreceptor Antagonists Image Figure 10. NRTIs Image Figure 11. Entry and Fusion Inhibitors Image Figure 12. Integrase Inhibitors Image Figure 13. Global Human Immunodeficiency Virus (HIV) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Human Immunodeficiency Virus (HIV) Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Human Immunodeficiency Virus (HIV) Sales Value Share by Type (2021-2032) Figure 16. Clinics Image Figure 17. Hospitals Image Figure 18. Labs Image Figure 19. Global Human Immunodeficiency Virus (HIV) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Human Immunodeficiency Virus (HIV) Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Human Immunodeficiency Virus (HIV) Sales Value Share by Application (2021-2032) Figure 22. Global Human Immunodeficiency Virus (HIV) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Human Immunodeficiency Virus (HIV) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Human Immunodeficiency Virus (HIV) Sales Value (2021-2032) & (US$ Million) Figure 25. North America Human Immunodeficiency Virus (HIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Human Immunodeficiency Virus (HIV) Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Human Immunodeficiency Virus (HIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Human Immunodeficiency Virus (HIV) Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Human Immunodeficiency Virus (HIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Human Immunodeficiency Virus (HIV) Sales Value (2021-2032) & (US$ Million) Figure 31. South America Human Immunodeficiency Virus (HIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Human Immunodeficiency Virus (HIV) Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Human Immunodeficiency Virus (HIV) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Protease Inhibitors
  • NNRTIs
  • Coreceptor Antagonists
  • NRTIs
  • Entry and Fusion Inhibitors
  • Integrase Inhibitors
Applications
  • Clinics
  • Hospitals
  • Labs
Companies covered
  • Merck & Co., Inc.
  • Mylan
  • AbbVie
  • ViiV Healthcare
  • Genentech, Inc.
  • Genentech, Inc.
  • Cipla, Inc.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Boehringer Ingelheim GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Immunodeficiency Virus (HIV) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Immunodeficiency Virus (HIV) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human Immunodeficiency Virus (HIV) Market Dynamics
  1. 2.1 Human Immunodeficiency Virus (HIV) Industry Trends
  2. 2.2 Human Immunodeficiency Virus (HIV) Industry Drivers
  3. 2.3 Human Immunodeficiency Virus (HIV) Industry Opportunities and Challenges
  4. 2.4 Human Immunodeficiency Virus (HIV) Industry Restraints
3 Human Immunodeficiency Virus (HIV) Market by Company
  1. 3.1 Global Human Immunodeficiency Virus (HIV) Company Revenue Ranking in 2025
  2. 3.2 Global Human Immunodeficiency Virus (HIV) Revenue by Company (2021-2026)
  3. 3.3 Global Human Immunodeficiency Virus (HIV) Company Ranking (2024-2026)
  4. 3.4 Global Human Immunodeficiency Virus (HIV) Company Manufacturing Base and Headquarters
  5. 3.5 Global Human Immunodeficiency Virus (HIV) Company Product Type and Application
  6. 3.6 Global Human Immunodeficiency Virus (HIV) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human Immunodeficiency Virus (HIV) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human Immunodeficiency Virus (HIV) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human Immunodeficiency Virus (HIV) Market by Type
  1. 4.1 Human Immunodeficiency Virus (HIV) Type Introduction
  2. 4.1.1 Protease Inhibitors
  3. 4.1.2 NNRTIs
  4. 4.1.3 Coreceptor Antagonists
  5. 4.1.4 NRTIs
  6. 4.1.5 Entry and Fusion Inhibitors
  7. 4.1.6 Integrase Inhibitors
  8. 4.2 Global Human Immunodeficiency Virus (HIV) Sales Value by Type
  9. 4.2.1 Global Human Immunodeficiency Virus (HIV) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Human Immunodeficiency Virus (HIV) Sales Value by Type (2021-2032)
  11. 4.2.3 Global Human Immunodeficiency Virus (HIV) Sales Value Share by Type (2021-2032)
5 Human Immunodeficiency Virus (HIV) Market by Application
  1. 5.1 Human Immunodeficiency Virus (HIV) Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Labs
  5. 5.2 Global Human Immunodeficiency Virus (HIV) Sales Value by Application
  6. 5.2.1 Global Human Immunodeficiency Virus (HIV) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Immunodeficiency Virus (HIV) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Human Immunodeficiency Virus (HIV) Sales Value Share by Application (2021-2032)
6 Human Immunodeficiency Virus (HIV) Regional Value Analysis
  1. 6.1 Global Human Immunodeficiency Virus (HIV) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Immunodeficiency Virus (HIV) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human Immunodeficiency Virus (HIV) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human Immunodeficiency Virus (HIV) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Immunodeficiency Virus (HIV) Sales Value (2021-2032)
  7. 6.3.2 North America Human Immunodeficiency Virus (HIV) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human Immunodeficiency Virus (HIV) Sales Value (2021-2032)
  10. 6.4.2 Europe Human Immunodeficiency Virus (HIV) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human Immunodeficiency Virus (HIV) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human Immunodeficiency Virus (HIV) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human Immunodeficiency Virus (HIV) Sales Value (2021-2032)
  16. 6.6.2 South America Human Immunodeficiency Virus (HIV) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human Immunodeficiency Virus (HIV) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human Immunodeficiency Virus (HIV) Sales Value Share by Country, 2025 VS 2032
7 Human Immunodeficiency Virus (HIV) Country-level Value Analysis
  1. 7.1 Global Human Immunodeficiency Virus (HIV) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Immunodeficiency Virus (HIV) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human Immunodeficiency Virus (HIV) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human Immunodeficiency Virus (HIV) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human Immunodeficiency Virus (HIV) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human Immunodeficiency Virus (HIV) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human Immunodeficiency Virus (HIV) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co., Inc.
  2. 8.1.1 Merck & Co., Inc. Company Information
  3. 8.1.2 Merck & Co., Inc. Business Overview
  4. 8.1.3 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
  6. 8.1.5 Merck & Co., Inc. Recent Developments
  7. 8.2 Mylan
  8. 8.2.1 Mylan Company Information
  9. 8.2.2 Mylan Business Overview
  10. 8.2.3 Mylan Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mylan Human Immunodeficiency Virus (HIV) Product Portfolio
  12. 8.2.5 Mylan Recent Developments
  13. 8.3 AbbVie
  14. 8.3.1 AbbVie Company Information
  15. 8.3.2 AbbVie Business Overview
  16. 8.3.3 AbbVie Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Human Immunodeficiency Virus (HIV) Product Portfolio
  18. 8.3.5 AbbVie Recent Developments
  19. 8.4 ViiV Healthcare
  20. 8.4.1 ViiV Healthcare Company Information
  21. 8.4.2 ViiV Healthcare Business Overview
  22. 8.4.3 ViiV Healthcare Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ViiV Healthcare Human Immunodeficiency Virus (HIV) Product Portfolio
  24. 8.4.5 ViiV Healthcare Recent Developments
  25. 8.5 Genentech, Inc.
  26. 8.5.1 Genentech, Inc. Company Information
  27. 8.5.2 Genentech, Inc. Business Overview
  28. 8.5.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
  30. 8.5.5 Genentech, Inc. Recent Developments
  31. 8.6 Genentech, Inc.
  32. 8.6.1 Genentech, Inc. Company Information
  33. 8.6.2 Genentech, Inc. Business Overview
  34. 8.6.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
  36. 8.6.5 Genentech, Inc. Recent Developments
  37. 8.7 Cipla, Inc.
  38. 8.7.1 Cipla, Inc. Company Information
  39. 8.7.2 Cipla, Inc. Business Overview
  40. 8.7.3 Cipla, Inc. Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cipla, Inc. Human Immunodeficiency Virus (HIV) Product Portfolio
  42. 8.7.5 Cipla, Inc. Recent Developments
  43. 8.8 Bristol-Myers Squibb Company
  44. 8.8.1 Bristol-Myers Squibb Company Company Information
  45. 8.8.2 Bristol-Myers Squibb Company Business Overview
  46. 8.8.3 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Product Portfolio
  48. 8.8.5 Bristol-Myers Squibb Company Recent Developments
  49. 8.9 Boehringer Ingelheim GmbH
  50. 8.9.1 Boehringer Ingelheim GmbH Company Information
  51. 8.9.2 Boehringer Ingelheim GmbH Business Overview
  52. 8.9.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Product Portfolio
  54. 8.9.5 Boehringer Ingelheim GmbH Recent Developments
  55. 8.10 Boehringer Ingelheim GmbH
  56. 8.10.1 Boehringer Ingelheim GmbH Company Information
  57. 8.10.2 Boehringer Ingelheim GmbH Business Overview
  58. 8.10.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Product Portfolio
  60. 8.10.5 Boehringer Ingelheim GmbH Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst